This indicates that even if PD-1 blockade could partly overcome the tumor’s immune tolerance, the lack of cytotoxic T lymphocyte (CTL) activity within the tumor remains a barrier to achieving an effective anti-immune response against iCCA. The gene discussed is PRRT2; the disease is neoplasm.